In recent years, the discovery of gene mutations has developed individualized targeted therapy, especially for NSCLC patients with epidermal growth factor receptor (EGFR) mutation-positive, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) provide a good treatment outcome, but the problem of resistance has not been fully solved. This evidence concerns the gene EGFR and non-small cell lung carcinoma.